ReviewJournal of molecular medicine (Berlin, Germany)2020
Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period.
Review in Journal of molecular medicine (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07609043 (Impact of Prasterone on Cardiometabolic Indicators in Perimenopausal Women.), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Prasterone on Cardiometabolic Indicators in Perimenopausal Women.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Association of primary allostatic load mediators and metabolic syndrome (MetS): A systematic review.Frontiers in endocrinology · 2022Pooled it
- DHEA as a Biomarker of Stress: A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2021Pooled it
- Association between serum dehydroepiandrosterone sulfate levels and body weight status among US adults: findings from NHANES 2021-2023.Hormones (Athens, Greece) · 2026Article
- Association between serum dehydroepiandrosterone sulfate and type 2 diabetes in US adults with adiposity as a mediator.Medicine · 2026Article
- Sex and gender differences in metabolic dysfunction-associated liver disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Association of serum androgen levels with Framingham Cardiovascular Risk Score in individuals with obesity.BMC endocrine disorders · 2026Article
- The bidirectional gut microbiota-inflammation axis in gestational diabetes mellitus: pathogenesis, long-term outcomes, and therapeutic perspectives.Frontiers in endocrinology · 2026Review
- Moderate increase in dietary fat induces alterations of microbiota and metabolome along the digestive tract prior to systemic metabolic changes: insights from a pig model.Gut microbes · 2025Article
- Intracrine Formation of Steroid Hormones in Breast Cancer, Epidermal Keratinocyte, Dermal Fibroblast, and Adipocyte Cell Lines Measured by LC-MS/MS.International journal of molecular sciences · 2025Article
- Molecular mechanism underlying cardioprotective effect of dehydroepiandrosterone on endoplasmic reticulum stress induced apoptosis in human vascular smooth muscle cells and human umbilical vein endothelial cells.Frontiers in pharmacology · 2025Article
- Dehydroepiandrosterone inhibits ADAMTS expression via an ERK-dependent mechanism in chondrocytes.PloS one · 2024Article
- Review
- Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study.Frontiers in pharmacology · 2022Article
- Dehydroepiandrosterone inhibits vascular proliferation and inflammation by modulating the miR-486a-3p/NLRP3 axis.American journal of translational research · 2022Article
- UHPLC-MS/MS-Based Metabolomics and Clinical Phenotypes Analysis Reveal Broad-Scale Perturbations in Early Pregnancy Related to Gestational Diabetes Mellitus.Disease markers · 2022Article
- Metabolomic Profiles of Plasma Retinol-Associated Dyslipidemia in Men and Women.Frontiers in nutrition · 2021Article
- Randomized Controlled Study of the Effects of DHEA on the Outcome of IVF in Endometriosis.Evidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dehydroepiandrosterone (DHEA), mostly present as its sulfated ester (DHEA-S), is an anabolic hormone that naturally declines with age. Furthermore, it is the most abundant androgen and estrogen precursor in humans. Low plasma levels of DHEA have been strongly associated with obesity, insulin resistance, dyslipidemia, and high blood pressure, increasing the risk of cardiovascular disease. In this respect, DHEA could be regarded as a promising agent against metabolic syndrome (MetS) in postmenopausal women, since several age-related metabolic diseases are reported during aging. There are plenty of experimental evidences showing beneficial effects after DHEA therapy on carbohydrate and lipid metabolism, as well as cardiovascular health. However, its potential as a therapeutic agent appears to attract controversy, due to the lack of effects on some symptoms related to MetS. In this review, we examine the available literature regarding the impact of DHEA therapy on adiposity, glucose metabolism, and the cardiovascular system in the postmenopausal period. Both clinical studies and in vitro and in vivo experimental models were selected, and where possible, the main cellular mechanisms involved in DHEA therapy were discussed. Schematic representation showing some of the general effects observed after administration DHEA therapy on target tissues of energy metabolism and the cardiovascular system. ↑ represents an increase, ↓ represents a decrease, - represents a worsening and ↔ represents no change after DHEA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.